In a statement, a Lilly spokesperson said the businesses were “threatening patient safety by falsely promoting supposedly ‘personalized’ compounded tirzepatide and misleading consumers about the ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Review the current Eli Lilly and Co (LLY:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if LLY is the best investment for you.

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound. Lilly hit as PBM drops Zepbound, but retains Wegovy ...

Shares in Eli Lilly rose sharply in pre-market trading today after the company reported the first phase 3 results for orforglipron, a GLP-1 agonist that it hopes will offer an oral alternative to ...